Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 8/2016

01-08-2016 | Myocardial Disease (M Patel, Section Editor)

Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline

Authors: Ariane Fraiche, Andrew Wang

Published in: Current Cardiology Reports | Issue 8/2016

Login to get access

Abstract

Since publication of the 2011 American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy (HCM), more recent studies offer greater insights about this condition. With increased recognition of the role of sarcomere protein mutations and myocardial structural abnormalities in the pathophysiology of this disease, new evidence offers potential improvements for the management of patients with HCM. In this review of studies published since 2011, we highlight several studies that may impact diagnostic considerations, risk stratification, and treatment of symptoms in HCM.
Literature
1.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761–96.CrossRefPubMed
2.
Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785–9.CrossRefPubMed
3.
Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705–15.CrossRefPubMed
4.
Semsarian C, Ingles J, Maron M, Maron B. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54.CrossRefPubMed
5.
Ho CY, Lakdawala NK, Cirino AL, Lipshultz SE, et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. J Am Coll Cardiol Heart Fail. 2015;3(2):180–8.
6.
Maron BJ, Ommen SR, Semsarian C, Spirito P, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83–99.CrossRefPubMed
7.
Captur G, Lopes LR, Mohun TJ, Patel V, et al. Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014;7:863–71.CrossRefPubMedPubMedCentral
8.
Ho CY, Abbasi SA, Neilan TG, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(3):415–22.CrossRefPubMedPubMedCentral
9.
Bogaert K, Olivotto I. MR Imaging in hypertrophic cardiomyopathy: from magnet to bedside. Radiology. 2014;273(2):329–48.CrossRefPubMed
10.
Fontana M, Banypersad SM, Treibel TA, Maestrini V, et al. Native T1 mapping in transthyretin amyloidosis. J Am Coll Cardiol Cardiovasc Imaging. 2014;7(2):157–65.CrossRef
11.
Sado DM, White SK, Piechnik SK, Banypersad SM, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6(3):392–8.CrossRefPubMed
12.
Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733.CrossRef
13.
Maron BJ, Casey SA, Poliac LC, Gohman TE, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. J Am Med Assoc. 1999;281(7):650–5.CrossRef
14.
Maron BJ, Rowin EJ, Casey SA, Link MS, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65(18):1915–28.CrossRefPubMed
15.
Maron BJ, Casey SA, Chan RH, Garberich RF, et al. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116:757–64.CrossRefPubMed
16.
Masri A, Pierson LM, Smedira NG, Agarwal S, et al. Predictors of long term outcomes in patient with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J. 2015;169(5):684–92.CrossRefPubMed
17.
Desai MY, Bhonsale A, Patel P, Naji P, et al. Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract predicts long-term outcomes. J Am Coll Cardiol Cardiovasc Imaging. 2014;7(1):26–36.CrossRef
18.
Spirito P, Autore C, Formisano F, Assenza GE, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113:1550–5.CrossRefPubMed
19.
Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Cardiovasc Imaging. 2012;5(4):370–7.CrossRef
20.
Briasoulis A, Mallikethi-Reddy S, Palla M, Alash I, et al. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101:1406–11.CrossRefPubMed
21.•
Chan RH, Maron BJ, Olivotto I, Pencina MJ. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484–95. This multicenter, observational HCM cohort study evaluated the prognostic significance of late gadolinium enhancement (LGE) by cardiac MRI and found that extent of LGE was associated with an increased risk of SCD events (LGE of ≥15% of LV mass demonstrated a 2-fold increase) in long term follow-up.CrossRefPubMed
22.
Kramer CM, Appelbaum E, Desai MY, Desvigne-Nickens P, et al. Hypertrophic cardiomyopathy registry: the rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015;170(2):223–30.CrossRefPubMed
23.
Maron MS, Rowin EJ, Olivotto I, Casey SA, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67(12):1399–409.CrossRefPubMed
24.
Tower-Rader A, Furiasse N, Puthumana JJ, Kruse J, et al. Effects of septal myomectomy on left ventricular diastolic function and left atrial volume in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014;114:1568–72.CrossRefPubMed
25.
Viresendorp PA, Schinkel AFL, Soliman OII, Kofflard MJM, et al. Long-term benefit of myomectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015;115:670–67.CrossRef
26.
Sorajja P, Ommen SR, Holmes DR, Dearani JA, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374–80.CrossRefPubMed
27.
Liebregts M, Steggerda RC, Vriesendorp PA, van Velzen H, Schinkel AF, Willems R, et al. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. J Am Coll Cardiol Cardiovasc Interv. 2016;9(5):463–9.CrossRef
28.•
Coppini R, Ferrantini C, Yao L, Fan P, et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127:575–84. This study showed that ranolazine, a late sodium channel antagonist, partially reversed cellular abnormalities in HCM myocytes in vitro. These results are the basis for the ongoing multicenter, randomized, controlled trial of a novel, late sodium channel antagonist, eleclazine, in symptomatic HCM patients.CrossRefPubMed
29.
Olivotto I, Hellawell JL, Farzaneh-Far R, Blair C. Approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial. Circ Heart Fail. 2016;9:e002764.CrossRefPubMed
30.•
Green EM, Wakimoto H, Anderson RL, Evanchik MJ, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;352:617–21. This study found that a novel agent that reduces contractility by decreasing the adenosine triphosphatase activity of the cardiac myosin heavy chain prevented the pathologic changes in the myocardium of mice with human HCM sarcomere mutation.CrossRef
31.
Coats CJ, Rantell K, Bartnik A, Patel A, et al. Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circ Heart Fail. 2015;8(6):1022–31.PubMed
32.
Axelsson A, Iversen K, Veijlstrup N, Norsk J. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3:123–31.CrossRefPubMed
33.
Santangeli P, Biase LD, Themistoclakis S, Raviele A, et al. Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence. Circ Arrhythmia and Electrophysiology. 2013;6:1089–94.CrossRefPubMed
34.
Contreras-Valdes FM, Buxton AE, Josephson ME, Anter E. Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(14):1485–7.CrossRefPubMed
35.
Zhao DS, Shen Y, Zhang Q, Lin G, et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace. 2015.
Metadata
Title
Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline
Authors
Ariane Fraiche
Andrew Wang
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 8/2016
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-016-0751-8

Other articles of this Issue 8/2016

Current Cardiology Reports 8/2016 Go to the issue

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

Bioresorbable Stents in PCI

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease

Cardiac PET, CT, and MRI (SE Petersen and F Pugliese, Section Editors)

Aortic Stenosis, a Left Ventricular Disease: Insights from Advanced Imaging

Valvular Heart Disease (A Wang, Section Editor)

Current Discoveries and Interventions for Barlow’s Disease

Cardiovascular Genomics (TL Assimes, Section Editor)

Genetics of Insulin Resistance and the Metabolic Syndrome

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits